AbbVie to Acquire Apogee Therapeutics for 10.9 Billion
AbbVie has agreed to purchase biotech firm Apogee Therapeutics in a cash deal valued at 10.9 billion dollars. The acquisition is intended to strengthen the company's immunology pipeline with next-generation treatments.
Xurve View
Insights:
Xurve View
ABBVIE INC will acquire biotech APOGEE THERAPEUTICS INC for $10.9 billion in cash. The deal, announced on Monday morning, marks a major expansion of the buyer's next-generation immunology pipeline. This acquisition signals a transition toward new growth drivers as the pharmaceutical giant navigates the post-patent era of its legacy blockbusters.
